Spinocerebellar ataxia type 6

Handb Clin Neurol. 2012;103:461-73. doi: 10.1016/B978-0-444-51892-7.00029-2.


The autosomal dominant spinocerebellar ataxias (SCA) are a genetically heterogeneous group of neurodegenerative disorders characterized by progressive motor incoordination, in some cases with ataxia alone and in others in association with additional progressive neurological deficits. Spinocerebellar ataxia type 6 (SCA6) is the prototype of a pure cerebellar ataxia, associated with a severe form of progressive ataxia and cerebellar dysfunction. SCA6, originally classified as such by Zhuchenko et al. (1997), is caused by a CAG repeat expansion in the CACNA1A gene which encodes the α1A subunit of the P/Q-type voltage-gated calcium channel. SCA6 is one of ten polyglutamine-encoding CAG nucleotide repeat expansion disorders comprising other neurodegenerative disorders such as Huntington's disease. The present review describes clinical, genetic, and pathological manifestations associated with this illness. Currently, there is no treatment for this neurodegenerative disease. Successful therapeutic strategies must target a valid pathological mechanism; thus, understanding the underlying mechanisms of disease is crucial to finding a proper treatment. Hence, this chapter will discuss as well the molecular mechanisms possibly associated with SCA6 pathology and their implication for the development of future treatment.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acetazolamide / therapeutic use
  • Anticonvulsants / therapeutic use
  • Calcium Channels / genetics*
  • Humans
  • Models, Biological
  • Neuroimaging
  • Peptides / genetics*
  • Spinocerebellar Ataxias / diagnosis*
  • Spinocerebellar Ataxias / drug therapy
  • Spinocerebellar Ataxias / epidemiology
  • Spinocerebellar Ataxias / genetics*


  • Anticonvulsants
  • CACNA1A protein, human
  • Calcium Channels
  • Peptides
  • polyglutamine
  • Acetazolamide